SUNNYVALE, Calif. - Accuray Incorporated (Nasdaq: ARAY) announced today that the company will highlight new CyberKnife® and TomoTherapy® technologies at the European Society for Therapeutic Radiology and Oncology (ESTRO) meeting, booth #2100, in Barcelona, Spain, April 24 - 27, 2015. The CyberKnife and TomoTherapy Systems are used to treat cancerous and benign tumors throughout the body. Each system precisely targets the tumor, delivering the prescribed radiation dose, while minimizing exposure to nearby healthy organs and tissues. At ESTRO, Accuray will showcase:
-- The new Delivery Analysis Software for the TomoTherapy System: added
confidence for every patient, every fraction, through a new tool that
provides unprecedented access to treatment delivery information.
-- The InCise™ Multileaf Collimator for the CyberKnife M6™ System:
improves treatment efficiency for a broader range of tumor types.
-- An enhanced Synchrony® Respiratory Tracking System for the CyberKnife
System: makes it even easier for clinicians to know they are precisely
tracking and adjusting for moving targets.
-- Multiple educational opportunities: thought leaders discuss changes in
radiation therapy treatments over the last 30 years during our satellite
symposium - titled "Radiation Therapy: Connecting History, Innovation
and Patients." A series of presentations from CyberKnife and TomoTherapy
users within the Accuray Exchange in Radiation Oncology (AERO™)
Academy provides the opportunity to learn about best practices.
-- Clinical evidence for both the CyberKnife and TomoTherapy Systems:
access to 100 presentations/posters is available on the ESTRO website.
For more information please visit Accuray website.
The new Delivery Analysis Software for the TomoTherapy System
Delivery Analysis for the TomoTherapy System recently received 510(k) clearance from the U.S. Food and Drug Administration (FDA), in conjunction with the CE Mark in the European Union. The Delivery Analysis software is an innovative tool that leverages the unique architecture of the TomoTherapy System to provide unprecedented access to treatment delivery information. The software provides enhanced confidence in system performance before each treatment, and actionable insights to help ensure all treatments stay on track. A pre-treatment test of the multileaf collimator (MLC) checks for differences between expected and measured MLC performance using pulse-by-pulse detector signals. Additionally, an in-treatment analysis of each delivered fraction is generated from exit detector data. It allows physicians to see if a particular fraction was not delivered as expected and helps to clarify the nature of the issue that led to the dose miss observed.
An enhanced Synchrony® Respiratory Tracking System for the CyberKnife System
The Synchrony System is the only clinically proven system that uses continual image guidance to automatically adjust the movement of the beam in synchronization with movement of the target volume. This new technology enables clinicians to:
-- Improve their ability to track moving targets and minimize treatment
-- Confidently set up Synchrony Respiratory Tracking with just a few mouse
-- Set up and treat moving targets, in particular lung cases, faster and
Satellite Symposium: "Radiation Therapy: Connecting History, Innovation and Patients"
The symposium will be held on Saturday, 25 April 2015 from 13:15 to 14:30, room 111 (level 1). Presentations will explore the progress that has been made over the last 30 years in radiation therapy and discuss Accuray's contribution to setting the standard for the precise treatments that are used today and will be used in the future. Chaired by Prof. Jurgen Peter Debus, M.D., Ph.D., Managing Director of the Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany, Symposium speakers will include: Dr. Cary Adams, CEO, the Union for International Cancer Control (UICC) and Chair of the NCD Alliance in Geneva, Switzerland; Prof. Ben J.M. Heijmen, Ph.D., Head of the Section of Medical Physics, Department of Radiation Oncology, Erasmus Medical Center, Rotterdam, The Netherlands; and Prof. Thomas Rockwell Mackie, Ph.D., Emeritus Professor, Departments of Medical Physics and Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, USA.
Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments.
Contact: Beth Kaplan, Accuray, +1 (408) 789-4426, email@example.com
Web Site: http://www.accuray.com